Developing strategies for liver fibrosis treatment
Developing strategies for liver fibrosis treatment
Liver fibrosis represents a major worldwide healthcare burden. Current therapy is limited to removing the causal agent. This approach is successful in some diseases; particularly haemochromatosis and chronic viral hepatitis. However, for many patients treatment is not possible, while other patients present to medical attention at an advanced stage of fibrosis. There is therefore a great need for novel therapies for liver fibrosis. The hepatic stellate cell has been recognised to be responsible for most of the excess extracellular matrix observed in chronic liver fibrosis. The detailed understanding of hepatic stellate cell biology has allowed the rational design of novel antifibrotic therapies. This review describes for the general reader the novel emerging therapies for liver fibrosis.
1575-1585
Murphy, Frank
e930f640-f880-4fc6-9f54-376a2d8aace7
Arthur, Michael
688445bc-6e6b-4973-8944-9ca04d942f21
Iredale, John
db99ade5-cefc-4712-ba93-cf09c27288d8
2002
Murphy, Frank
e930f640-f880-4fc6-9f54-376a2d8aace7
Arthur, Michael
688445bc-6e6b-4973-8944-9ca04d942f21
Iredale, John
db99ade5-cefc-4712-ba93-cf09c27288d8
Murphy, Frank, Arthur, Michael and Iredale, John
(2002)
Developing strategies for liver fibrosis treatment.
Expert Opinion on Investigational Drugs, 11 (11), .
(doi:10.1517/13543784.11.11.1575).
Abstract
Liver fibrosis represents a major worldwide healthcare burden. Current therapy is limited to removing the causal agent. This approach is successful in some diseases; particularly haemochromatosis and chronic viral hepatitis. However, for many patients treatment is not possible, while other patients present to medical attention at an advanced stage of fibrosis. There is therefore a great need for novel therapies for liver fibrosis. The hepatic stellate cell has been recognised to be responsible for most of the excess extracellular matrix observed in chronic liver fibrosis. The detailed understanding of hepatic stellate cell biology has allowed the rational design of novel antifibrotic therapies. This review describes for the general reader the novel emerging therapies for liver fibrosis.
This record has no associated files available for download.
More information
Published date: 2002
Identifiers
Local EPrints ID: 27284
URI: http://eprints.soton.ac.uk/id/eprint/27284
ISSN: 1354-3784
PURE UUID: c3e9a522-5342-447d-8f8a-696c808d5161
Catalogue record
Date deposited: 26 Apr 2006
Last modified: 15 Mar 2024 07:17
Export record
Altmetrics
Contributors
Author:
Frank Murphy
Author:
Michael Arthur
Author:
John Iredale
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics